Epitalon vs MOTS-c
These records contribute different pieces to the question of what a life could contain. Each piece comes from a particular subject and experiment.
Subjects and outcomes
| Question | MOTS-c | Epitalon |
|---|---|---|
| Where does it come from? | 16 amino acids encoded in mitochondrial DNA; the MOTS-c review describes MT-RNR1. | Synthetic Ala-Glu-Asp-Gly, modelled on the pineal extract Epithalamin; see the Epitalon overview. |
| Which animal outcome is most relevant here? | Running capacity, grip strength and gait in aged mice. | Maximum lifespan increased 12.3% in female SHR mice; mean lifespan unchanged. |
| Which cellular finding stands out? | Stress-induced movement into the nucleus in human and mouse cells; direct CK2 binding in cell-free assays with supporting mouse work. | Telomerase activation in human fetal fibroblasts; telomere extension in normal and cancer cell lines through differing routes. |
| What happened in the human research? | Circulating MOTS-c tracked outcomes in 94 haemodialysis patients. Endogenous-marker observation. | Lower mortality was associated with Epithalamin in 266 elderly people. Parent-extract observation, without randomisation or placebo. |
Choosing a research question
For physical capacity, the MOTS-c mouse work gives me the more direct starting point. For chromosome-end maintenance, Epitalon has the additional human cell-line work in 2025. These are preferences about questions worth pursuing; the subjects and outcomes in the table define their reach.
There is no head-to-head human trial here, and no established human benefit from either administered peptide. Combining the two bodies of research cannot create that missing result. A careful human function study of either would bring the practical question much closer to an answer.
Approval and safety
MOTS-c has no FDA approval for any use; its research-labelled preparations are sold for laboratory work, while prescription care starts with an individual clinical assessment. Epitalon has no FDA, EMA or MHRA approval and no registered indication. Neither has validated human pharmacokinetics or controlled long-term human safety evidence.
The questions page deals with dosing requests and the separate sporting restrictions. The healthspan page returns to the practical outcome at the heart of this site: what the years allow a person to do.